

Fungemia and other Fungal Infections Associated with Use of *Saccharomyces boulardii* Probiotic Supplements

Juha Rannikko, Ville Holmberg, Matti Karppelin, Pertti Arvola, Reetta Huttunen, Eero Mattila, Niina Kerttula, Teija Puhto, Ülle Tamm, Irma Koivula, Risto Vuento, Jaana Syrjänen, Ulla Hohenthal



In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 **AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at <http://www.medscape.org/journal/eid>; and (4) view/print certificate. For CME questions, see page XXX.

Release date: July 14, 2021; Expiration date: July 14, 2022

Learning Objectives

Upon completion of this activity, participants will be able to:

- Describe the use and clinical characteristics of *Saccharomyces boulardii* (Sb) probiotic yeast among patients with *Saccharomyces* fungemia, according to a retrospective registry study of all *Saccharomyces* sp. findings during 2009–2018 in 5 university hospitals in Finland
- Determine the use of Sb probiotic yeast among patients with positive *Saccharomyces* culture findings in samples other than blood, according to a retrospective registry study of all *Saccharomyces* sp. findings during 2009–2018 in 5 university hospitals in Finland
- Identify clinical implications of the use of Sb probiotic yeast among patients with *Saccharomyces* fungemia or other positive *Saccharomyces* culture findings, according to a retrospective registry study of all *Saccharomyces* sp. findings during 2009–2018 in 5 university hospitals in Finland

CME Editor

Thomas J. Gryczan, MS, Technical Writer/Editor, Emerging Infectious Diseases. *Disclosure: Thomas J. Gryczan, MS, has disclosed no relevant financial relationships.*

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. *Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.*

Authors

Disclosures: Juha Rannikko, MD, PhD; Ville Holmberg, MD, PhD; Matti Karppelin, MD, PhD; Pertti Arvola, MD, PhD; Reetta Huttunen, MD, PhD; Eero Mattila, MD, PhD; Niina Kerttula, MD, MS; Teija Puhto, MD, PhD; Ülle Tamm, MD; Irma Koivula, MD, PhD; Risto Vuento, MD, PhD; and Jaana Syrjänen, MD, PhD, have disclosed no relevant financial relationships. Ulla Hohenthal, MD, PhD, has disclosed the following relevant financial relationships: served as an advisor or consultant for GlaxoSmithKline; other (Congress Travel) for Grifols Nordic AB; Merck Sharp & Dohme GmbH.

Author affiliations: Tampere University, Tampere, Finland (J. Rannikko); Tampere University Hospital, Tampere (J. Rannikko, M. Karppelin, P. Arvola, R. Huttunen, J. Syrjänen); University of Helsinki, Helsinki, Finland (V. Holmberg); Helsinki University Hospital, Helsinki (V. Holmberg, E. Mattila); Oulu

University Hospital, Oulu, Finland (N. Kerttula, T. Puhto); Kuopio University Hospital; Kuopio Finland (Ü. Tamm, I. Koivula); Fimlab Laboratories, Tampere (R. Vuento); Turku University Hospital, Turku, Finland (U. Hohenthal)
DOI: <http://doi.org/10.3201/eid2708.210018>

Because of widespread use of probiotics, their safety must be guaranteed. We assessed use of *Saccharomyces boulardii* probiotic yeast from medical records for patients who had *Saccharomyces* fungemia or other clinical *Saccharomyces* culture findings. We evaluated all *Saccharomyces* sp. findings at 5 university hospitals in Finland during 2009–2018. We found 46 patients who had *Saccharomyces* fungemia; at least 20 (43%) were using *S. boulardii* probiotic. Compared with a control group that had bacteremia or candidemia, the odds ratio for use of an *S. boulardii* probiotic was 14 (95% CI 4–44). Of 1,153 nonblood culture findings, the history for 125 patients was checked; at least 24 (19%) were using the probiotic (odds ratio 10, 95% CI 3–32). This study adds to published fungemia cases linked to use of *S. boulardii* probiotic and sheds light on the scale of nonblood *Saccharomyces* culture findings that are also linked to use of this probiotic.

Probiotics are live microorganisms intended to provide health benefits when consumed (1). Typically, the endpoint in randomized controlled trials of probiotics has been the prevention of diarrhea or faster alleviation of diarrhea symptoms (2). Regarding their safety, serious adverse effects have been rare in probiotic studies (3). However, the adverse effects have not been fully reported (4). In 1 trial in which a multispecies probiotic preparation was given to patients who had severe acute pancreatitis, the mortality rate was higher in the probiotic arm (5). Nevertheless, the use of probiotics is common. According to the 2012 National Health Interview Survey in the United States, 1.6% of adults had used prebiotics or probiotics in the preceding 30 days (6).

Saccharomyces cerevisiae var. *boulardii* is a yeast that is used as a probiotic. In hospitals in the United States, the use of *S. cerevisiae* var. *boulardii* has been common, especially among elderly patients (7). This strain is difficult to distinguish microbiologically from *S. cerevisiae* because they have >99% genomic relatedness (8). Thus, in everyday clinical laboratory work, the *S. cerevisiae* var. *boulardii* strain is identified as either *Saccharomyces* sp. or *S. cerevisiae*. A review from 2005 considered *S. cerevisiae* var. *boulardii* to be the etiologic agent of *Saccharomyces* fungemia if the patient received treatment with a probiotic containing *S. cerevisiae* var. *boulardii* or if a molecular typing method confirmed the identification of this yeast (9). The authors found 37 cases in the literature. We found an additional 14 reports, including 22 cases of *Saccharomyces* fungemia with the same diagnostic method published after this review (10–23). Thus, before our study, 59 cases of fungemia with a link to the use of the probiotic had been published. All of these cases

have been either individual cases or small cases series (≤ 7 cases) without any systematic approach to quantify the problem.

Furthermore, besides fungemia, there are few reports on other clinically relevant microbiological findings for this yeast (i.e., in abscesses, ascites fluid, or the pleural cavity). The meta-analysis we mention listed 20 cases of findings other than fungemia (9). These findings are useful because they might also lead to a change in antimicrobial treatment.

We conducted a retrospective registry study (case series) at 5 university hospitals in Finland to evaluate the use of the *S. cerevisiae* var. *boulardii* probiotic in patients who had *Saccharomyces* fungemia or another clinical culture finding for this yeast. To evaluate the association between probiotic use and subsequent findings, we compared use of *S. cerevisiae* var. *boulardii* for patients who had a *Saccharomyces* infection with use of *S. cerevisiae* var. *boulardii* for patients who had an infection caused by another etiologic agent, such as bacteria or *Candida* sp.

Methods

Background

Finland has 5 university hospitals that are secondary referral centers of their catchment areas and tertiary referral centers for other hospital districts. Their combined catchment areas cover more than half population of Finland (3.29 million of 5.6 million persons). All university hospitals use the same register (SAI-registry; Neotide Ltd, <https://www.neotide.fi>), in which the local clinical microbial laboratory data are collected. These data cover all blood culture data and most of all other clinical microbial culture data of the catchment area of the university hospital.

Patient Data

At least 1 infectious diseases specialist in every university hospital collected the clinical data from the medical records for all blood culture-positive cases found in the register that were identified as *Saccharomyces* sp. or *S. cerevisiae*. The use of the *S. cerevisiae* var. *boulardii* probiotic was defined as use at the time of the positive culture or in the preceding 7 days. Data were collected on use during the preceding 3 months. If the medical record was not available, the case-patient was classified as not using a probiotic. The Quick SOFA score and the definition of septic shock were based on the Sepsis-3 definitions (24). The McCabe score was determined as reported by McCabe and Jackson (25). Data collected for case-patients who had nonblood cultures were age, sex,

malignancy, digestive tract disease, use of probiotics, use of antifungal medication at the time of the culture, and possible change of medication resulting from finding of *Saccharomyces* sp. The most recent 25 cases of nonblood culture findings in each hospital district were evaluated (excluding case-patients who had positive fecal samples). Isolates were obtained from routine laboratory bacterial and fungal cultures. The anatomic site of the culture was collected from the local hospital microbial registry (SAI) for all culture-positive cases. Abdominal sites were those in which culture was taken from, for example, ascites fluid, a biliary drainage catheter, or abscess drainage fluid, but not from skin or wound secretions. Oral and respiratory tract samples were from sinus drainage, bronchial lavage cultures, and pleural drainage. Other sites included samples from perianal abscesses, mediastinum, and urine.

Control Group

To evaluate the practice of probiotic use in the hospital ward in which the patient who had a *Saccharomyces* finding was given treatment, a control group was obtained from the same SAI register. For every *Saccharomyces* fungemia case-patient, 2 blood culture-positive patients (1 chronologically closest before and 1 after) from the same ward as the case were selected. For every clinical culture sample (other than blood), there was 1 chronologically closest positive culture sample from the same ward as the case-patient who served as a control. Data collected for the controls were date, ward, microbe, age, sex, malignancy, digestive tract disease, and *S. cerevisiae* var. *boulardii* probiotic use at the time of the positive culture or in the previous 3 months.

Statistical Analysis

We used SPSS version 22.0 software (IBM Corp., <https://www.ibm.com>) for statistical analyses. The study was centrally approved by the Ethics Committee of Tampere University Hospital, Tampere, Finland. The requirement for informed consent was waived.

Results

Blood Cultures

There were 46 patients with a positive blood culture for *Saccharomyces* in the 5 hospitals during between January 2009–December 2018. The median age of case-patients was 68 (range 30–93) years and a male predominance (63%). The most common underlying condition was a digestive tract disease (59%). There was a medical record confirming the use of the

S. cerevisiae var. *boulardii* probiotic on the day of the blood culture or during the preceding 7 days for 20 case-patients (43%). Medical records were not available for 10 case-patients (22%), and these were classified as nonusers.

Of the 20 case-patients, 17 were using *S. cerevisiae* var. *boulardii* probiotic on the day of the blood culture and 3 case-patients had already stopped using it (2 patients on the day before and 1 patient 5 days earlier). Five additional case-patients had used the probiotic in the preceding 3 months, of whom 1 patient had already stopped using it 26 days earlier. For 4 case-patients, the time when the use of the probiotic was terminated could not be determined. Most case-patients (16/20, 80%) received the *S. cerevisiae* var. *boulardii* probiotic in the hospital, 3 case-patients in some other facility, and 1 case-patient was using it at home. All *S. cerevisiae* var. *boulardii* probiotics found in the medical records were from the same strain (Precosa; Biocodex Ltd., <https://www.biocodex.com>). We provide characteristics, underlying diseases, and severity of the disease for these patients (Table 1, <https://wwwnc.cdc.gov/EID/article/27/8/21-0018-T1.htm>; Table 2).

Antimicrobial drugs were commonly used by the patients (72%) during 4 weeks preceding the fungemia. Antifungal treatment was commenced or changed because of *Saccharomyces* fungemia for 23 patients (50%). For an additional 8 patients (17%), the culture result came after the patient had died. Case-fatality rates by day 7 were 22% (10 patients) and by day 28 were 37% (17 patients). Of patients who died by day 28, 6 patients had an ultimately fatal disease (McCabe score 2) and 5 patients had a rapidly fatal disease (McCabe score 3).

Nonblood Cultures

There were 1,153 nonblood *Saccharomyces* culture findings (fecal samples excluded). There was considerable variation between hospital districts in numbers of the microbial cultures and anatomic sites from which cultures were obtained (Table 3). We evaluated use of probiotics for 125 case-patients. Medical records were not available for 6 of them. Use of *S. cerevisiae* var. *boulardii* probiotic was confirmed for 24 case-patients (19%). This finding was divided by the anatomic site as follows: 17 (21%) of 82 from the abdominal region, 4 (13%) of 30 from the oral or respiratory tract, and 3 (23%) of 13 from other sites. Antifungal medication was already in use at the time of culture for 38% (47/125, the medical record was not available for 1 case-patient) of the case-patients. This finding led to a modification of the antifungal

SYNOPSIS

Table 2. Characteristics of 46 case-patients who had *Saccharomyces* fungemia in 5 hospital districts, Finland, January 1, 2009–December 31, 2018*

Characteristic	Value
No. patients	46
Median age, y (range)	68 (30–93)
Sex	29 (63)
M	29 (63)
F	17 (37)
Use of <i>S. cerevisiae</i> var. <i>boulardii</i> probiotic in preceding 3 mo†	25/46 (54)
Use of <i>S. cerevisiae</i> var. <i>boulardii</i> probiotic in preceding 7 d†	20/46 (43)
Use of <i>S. cerevisiae</i> var. <i>boulardii</i> probiotic in preceding 7 d in control group‡	4/76 (5)
Central venous catheter	8 (17)
Use of antimicrobial drugs in preceding 4 weeks	33 (72)
Change in antimicrobial drugs because of fungemia	23 (50)
Underlying diseases	
Digestive tract	27 (59)
Neurologic	11 (24)
Cardiovascular	8 (17)
Solid tumor with metastasis	6 (13)
Diabetes mellitus (any type)	6 (13)
Pulmonary	5 (11)
Liver	4 (9)
Rheumatic	4 (9)
Chronic kidney§	3 (7)
McCabe score†	
No or nonfatal underlying disease	22 (48)
Ultimately fatal underlying diseases (<5 y)	9 (20)
Rapidly fatal underlying diseases (<1 y)	5 (11)
Severity of disease	
qSOFA score ≥ 2 at time of fungemia	16 (35)
Septic shock at time of fungemia	6 (13)
Death by day 7 after fungemia	10 (22)

*Values are no. (%) or no. positive/no. tested (%) unless otherwise indicated.

†Medical records were not available for 10 case-patients.

‡Medical records were not available for 6 control case-patients.

§History of creatinine level >120 $\mu\text{mol/L}$.

medication in for 35% (44/125, medical records not available for 2 case-patients) of the case-patients.

Controls

The controls for the fungemia case-patients ($n = 76$) were mostly bacteremic ($n = 65$), but there were 5 case-patients infected with *Candida* sp. Medical records were not available for 6 control case-patients. Median age for this group was 70 years (vs. 68 years for case-patients), 70% were males (versus 63% for the case-patients), 47% had digestive tract disease (vs. 59% of the case-patients), and 17% had a malignancy (vs. 13% of the case-patients) (data were available for 64 case-patients). Use of *S. cerevisiae* var. *boulardii* probiotic by the *Saccharomyces* fungemia group was 43% compared with 5% (4/76) for the control group (odds ratio [OR] 14, 95% CI 4–44).

Microbes detected for controls who had non-blood cultures ($n = 123$) were also mostly bacteria ($n = 97$), but *Candida* sp. or other yeasts ($n = 51$; with or without a concomitant bacterial finding) were more common than in blood cultures. Median age for this group was 65 years (vs. 64 years for case-patients), 44% were males (vs. 59% for case-patients), 70% had

digestive tract disease (vs. 69% of case-patients), and 28% had a malignancy (vs. 38% of case-patients) (data on underlying diseases were available for 100 controls). Use of *S. cerevisiae* var. *boulardii* probiotic was 19% (24/125) in the *Saccharomyces* culture-positive group compared with 2% (3/123) for the control group (OR 10, 95% CI 3–32).

Discussion

We report 20 cases of *Saccharomyces* fungemia in patients who used *S. cerevisiae* var. *boulardii* probiotic. These cases have increased the number of cases reported in the literature by 34%.

We evaluated 125 of 1,153 patients who had a nonblood *Saccharomyces* culture finding and confirmed use of *S. cerevisiae* var. *boulardii* probiotic by 19% of these case-patients. To our knowledge, the magnitude of findings other than fungemia has not been reported. Although some of these nonblood findings might represent colonization, positive *Saccharomyces* cultures led to a change in antimicrobial drugs for 44 (35%) patients who had evaluated cases.

We also evaluated use of *S. cerevisiae* var. *boulardii* probiotic for patients who had a *Saccharomyces* culture

finding and compared it with that of a control group who had different positive blood and nonblood cultures and were in the same ward around the same time. The *Saccharomyces* fungemia patients had an OR of 14 and nonblood culture-positive patients had an OR of 10 for use of this probiotic compared with respective controls. Moreover, case-patient 7 (Table 1) is an example of a patient in whom probiotic use unequivocally caused the fungemia. The patient had had a percutaneous endoscopic gastrostomy feeding tube inserted 2 days before the fungemia, had septic shock, and then died. The probiotic was administered at least once through the tube, and the tip of the tube was unintentionally displaced from its ventricular position, leading to an accidental peritoneal application of the probiotic.

Saccharomyces fungemias occurred most often in patients who had diseases of the gastrointestinal tract (59%). This finding is nearly identical to the amount reported in a meta-analysis (58%) (9). Furthermore, there are reports of *Saccharomyces* fungemias in patients not given pretreatment with a *S. cerevisiae* var. *boulardii* probiotic that have been believed to have been derived from contaminated central venous catheters (26–28).

Bacteremias and fungemias have not been encountered in clinical trials with probiotics in general. There were probiotic studies conducted with susceptible patients who did not have blood culture findings and who had hepatic encephalopathy (29). However, serious concurrent conditions have usually been an exclusion criterion; thus, the safety profile remains unclear. Furthermore, there are other reported safety issues with probiotics, such as contamination of a probiotic

supplement with a pathogenic microbe or possible transfer of an antimicrobial drug resistance gene from a probiotic microbe to pathogenic microbes (30–32).

Regarding the benefits of probiotics, is there evidence showing that adults should use *S. cerevisiae* var. *boulardii* probiotic in conjunction with antimicrobial drugs to prevent *Clostridioides difficile* infections (CDIs) that cause diarrhea? A meta-analysis during 2017 combined *S. cerevisiae* var. *boulardii* probiotic studies conducted in adult populations to prevent CDIs (33). There were 5 studies. All studies had a low number of CDIs (15 cases of CDI in control groups) and all had nonsignificant results (pooled risk ratio 0.63, 95% CI 0.29–1.37).

Currently, several companies sell *S. cerevisiae* var. *boulardii* yeast, but total consumption of this yeast in Finland is not known. Thus, we are not able to relate our study results to its use. However, nationwide consumption of probiotics does not reflect the risk for fungemia or nonblood culture findings, or use of this probiotic by susceptible patients in hospitals. Cautious use of *S. cerevisiae* var. *boulardii* probiotic in gastrointestinal surgery wards would probably be one of the most effective ways to decrease these culture findings.

Moreover, the benefits for the indication for which the probiotic is used need to be established. There are 2 recent US guidelines on administration of probiotics in general for primary prevention of CDI. The first guideline states that there are insufficient data to recommend the administration (34), and the second guideline states that in certain circumstances certain probiotics could be used, but the quality of evidence is low (35).

Table 3. *Saccharomyces* clinical culture findings (excluding fungemias), Finland, January 1, 2009–December 31, 2018*

Characteristic	All			University hospital district		
	Total	Helsinki	Tampere	Turku	Oulu	Kuopio
Catchment area in 2017	3,310,000	1,650,000	530,000	480,000	400,000	250,000
Inpatient days in 2017	1,814,183	784,252	307,484	294,834	191,612	236,001
Patients who had clinical findings	1,344	649	30	215	285	165
Abdominal region	205	67	21	8	76	33
Oral or respiratory tract	676	387	6	71	137	75
Fecal	191	53	1	130	4	3
Other or unspecified	272	142	2	6	68	54
Patients who had medical record of <i>Saccharomyces cerevisiae</i> var. <i>boulardii</i> probiotic per clinical finding†	24/125 (19)	3/25 (12)	6/25 (24)	4/25 (16)	4/25 (16)	7/25 (28)
Abdominal region	15	2	4	1	4	4
Oral or respiratory tract	4	0	1	3	0	0
Other or unspecified	5	1	1	0	0	3
Patients who had medical record of <i>S. cerevisiae</i> var. <i>boulardii</i> probiotic in control group	3/123 (2)	0/25 (0)	1/25 (4)	0/23 (0)	0/25 (0)	2/25 (8)
No. patients who had change of antimicrobial drugs because of finding of <i>Saccharomyces</i> sp.‡	44/125 (35)	11/25 (44)	3/25 (12)	8/25 (32)	13/25 (52)	9/25 (36)

*Values are no. or no. positive/no. tested (%).

†Fecal samples excluded. The most recent 25 case-patients per hospital district checked. Medical records not available for 6 case-patients. Kuopio last 3 mo of probiotic use, others last 7 d.

‡Medical records not available for 2 case-patients.

The first limitation of this study is that we were not able to obtain microbiological evidence that the fungal infections were caused by the *S. cerevisiae* var. *boulardii* probiotic strain and not by another strain. Furthermore, the retrospective design using medical records can lead to a bias in reporting. Only confirmed use of probiotics was reported in this study, and case-patients whose medical records were not available were defined as not using a probiotic. Thus, the percentage of probiotic users was the minimum estimate in all groups. All medications given to patients in the wards were documented in medical records of patients, but patients might have used these medications before they were admitted to the hospital. Moreover, most patients who had fungemia were given bacterial antimicrobial drugs, which could have decreased the routine of taking blood cultures. Recall bias (e.g., the *S. cerevisiae* var. *boulardii* probiotic would have been mentioned in the medical charts more often in case-patients than in control-patients because of *Saccharomyces* culture finding) was not a limitation in this study. For all but 1 case-patient, the probiotic was recorded in the charts before the culture result was complete.

S. cerevisiae var. *boulardii* probiotics are not recommended for patients who have indwelling catheters, are immunocompromised, or are critically ill. Our results indicate that use of *S. cerevisiae* var. *boulardii* probiotics should also be considered carefully for patients whose gastrointestinal tract integrity might be compromised. Furthermore, more data are needed to elucidate the health benefits of *S. cerevisiae* var. *boulardii* probiotics in general.

This study was supported by scholarships from the Finnish Medical Foundation (grant 2903 to J.R.) and Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (grant 92010 to R.H.).

About the Author

Dr. Rannikko is an infectious diseases consultant at Tampere University Hospital, Tampere, Finland, and clinical instructor at Tampere University. One of his primary research interests is the role of the infection in postbacteremic deaths.

References

- Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol*. 2014;11:506–14. <https://doi.org/10.1038/nrgastro.2014.66>
- McFarland LV. From yaks to yogurt: the history, development, and current use of probiotics. *Clin Infect Dis*. 2015;60(Suppl 2):S85–90. <https://doi.org/10.1093/cid/civ054>
- Sanders ME, Akkermans LM, Haller D, Hammerman C, Heimbach J, Hörmannspurger G, et al. Safety assessment of probiotics for human use. *Gut Microbes*. 2010;1:164–85. <https://doi.org/10.4161/gmic.1.3.12127>
- Bafeta A, Koh M, Riveros C, Ravaud P. Harms reporting in randomized controlled trials of interventions aimed at modifying microbiota: a systematic review. *Ann Intern Med*. 2018;169:240–7. <https://doi.org/10.7326/M18-0343>
- Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al.; Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008;371:651–9. [https://doi.org/10.1016/S0140-6736\(08\)60207-X](https://doi.org/10.1016/S0140-6736(08)60207-X)
- Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002–2012. *Natl Health Stat Report*. 2015;Feb 10:1–16.
- Yi SH, Jernigan JA, McDonald LC. Prevalence of probiotic use among inpatients: a descriptive study of 145 U.S. hospitals. *Am J Infect Control*. 2016;44:548–53. <https://doi.org/10.1016/j.ajic.2015.12.001>
- Khatiri I, Tomar R, Ganesan K, Prasad GS, Subramanian S. Complete genome sequence and comparative genomics of the probiotic yeast *Saccharomyces boulardii*. *Sci Rep*. 2017;7:371. <https://doi.org/10.1038/s41598-017-00414-2>
- Enache-Angoulvant A, Hennequin C. Invasive *Saccharomyces* infection: a comprehensive review. *Clin Infect Dis*. 2005;41:1559–68. <https://doi.org/10.1086/497832>
- Lolis N, Veldekis D, Moraitou H, Kanavaki S, Velegaki A, Triandafyllidis C, et al. *Saccharomyces boulardii* fungaemia in an intensive care unit patient treated with caspofungin. *Crit Care*. 2008;12:414. <https://doi.org/10.1186/cc6843>
- Santino I, Alari A, Bono S, Teti E, Marangi M, Bernardini A, et al. *Saccharomyces cerevisiae* fungemia, a possible consequence of the treatment of *Clostridium difficile* colitis with a probioticum. *Int J Immunopathol Pharmacol*. 2014;27:143–6. <https://doi.org/10.1177/039463201402700120>
- Fadhel M, Patel S, Liu E, Levitt M, Asif A. *Saccharomyces cerevisiae* fungemia in a critically ill patient with acute cholangitis and long term probiotic use. *Med Mycol Case Rep*. 2018;23:23–5. <https://doi.org/10.1016/j.mmcr.2018.11.003>
- Kara I, Yıldırım F, Özgen Ö, Erganiş S, Aydoğdu M, Dizbay M, et al. *Saccharomyces cerevisiae* fungemia after probiotic treatment in an intensive care unit patient. *J Mycol Med*. 2018;28:218–21. <https://doi.org/10.1016/j.mycmed.2017.09.003>
- Romanio MR, Coraine LA, Maielo VP, Abramczyc ML, Souza RL, Oliveira NF. *Saccharomyces cerevisiae* fungaemia in a pediatric patient after treatment with probiotics. *Rev Paul Pediatr*. 2017;35:361–4. <https://doi.org/10.1590/1984-0462/;2017;35;3;00014>
- Appel-da-Silva MC, Narvaez GA, Perez LR, Drehmer L, Lewgoy J. *Saccharomyces cerevisiae* var. *boulardii* fungemia following probiotic treatment. *Med Mycol Case Rep*. 2017;18:15–7. <https://doi.org/10.1016/j.mmcr.2017.07.007>
- Atıcı S, Soysal A, Karadeniz Cerit K, Yılmaz Ş, Aksu B, Kıyan G, et al. Catheter-related *Saccharomyces cerevisiae* fungemia following *Saccharomyces boulardii* probiotic treatment: in a child in intensive care unit and review of the literature. *Med Mycol Case Rep*. 2017;15:33–5. <https://doi.org/10.1016/j.mmcr.2017.02.002>

17. Roy U, Jessani LG, Rudramurthy SM, Gopalakrishnan R, Dutta S, Chakravarty C, et al. Seven cases of *Saccharomyces fungaemia* related to use of probiotics. *Mycoses*. 2017;60:375–80. <https://doi.org/10.1111/myc.12604>
18. Ellouze O, Berthoud V, Mervant M, Parthiot JP, Girard C. Septic shock due to *Saccharomyces boulardii*. *Med Mal Infect*. 2016;46:104–5. <https://doi.org/10.1016/j.medmal.2015.12.003>
19. Landaburu MF, Lopez Daneri GA, Relloso S, Zarlenga LJ, Vinante MA, Mujica MT. Fungaemia following *Saccharomyces cerevisiae* var. *boulardii* probiotic treatment in an elderly patient. *Rev Argent Microbiol*. 2019.
20. Popiel KY, Wong P, Lee MJ, Langelier M, Sheppard DC, Vinh DC. Invasive *Saccharomyces cerevisiae* in a liver transplant patient: case report and review of infection in transplant recipients. *Transpl Infect Dis*. 2015;17:435–41. <https://doi.org/10.1111/tid.12384>
21. Chioukh FZ, Ben Hmida H, Ben Ameer K, Toumi A, Monastiri K. *Saccharomyces cerevisiae* fungemia in a premature neonate treated receiving probiotics [in French]. *Med Mal Infect*. 2013;43:359–60. <https://doi.org/10.1016/j.medmal.2013.06.008>
22. Thygesen JB, Glerup H, Tarp B. *Saccharomyces boulardii* fungemia caused by treatment with a probioticum. *BMJ Case Rep*. 2012;2012(mar26 1):bcr0620114412. <https://doi.org/10.1136/bcr.06.2011.4412>
23. Ventoulis I, Sarmourli T, Amoiridou P, Mantzana P, Exindari M, Gioula G, et al. Bloodstream infection by *Saccharomyces cerevisiae* in two COVID-19 patients after receiving supplementation of *Saccharomyces* in the ICU. *J Fungi (Basel)*. 2020;6:98. <https://doi.org/10.3390/jof6030098>
24. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315:801–10. <https://doi.org/10.1001/jama.2016.0287>
25. McCabe W, Jackson G. Gram-negative bacteremia; I. Etiology and ecology. *Arch Intern Med*. 1962;110:847–55. <https://doi.org/10.1001/archinte.1962.03620240029006>
26. Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard JP, Ricour C, Jacquemin JL, et al. Possible role of catheters in *Saccharomyces boulardii* fungemia. *Eur J Clin Microbiol Infect Dis*. 2000;19:16–20. <https://doi.org/10.1007/s100960050003>
27. Lherm T, Monet C, Nougère B, Soulier M, Larbi D, Le Gall C, et al. Seven cases of fungemia with *Saccharomyces boulardii* in critically ill patients. *Intensive Care Med*. 2002;28:797–801. <https://doi.org/10.1007/s00134-002-1267-9>
28. Cassone M, Serra P, Mondello F, Girolamo A, Scafetti S, Pistella E, et al. Outbreak of *Saccharomyces cerevisiae* subtype *boulardii* fungemia in patients neighboring those treated with a probiotic preparation of the organism. *J Clin Microbiol*. 2003;41:5340–3. <https://doi.org/10.1128/JCM.41.11.5340-5343.2003>
29. Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. *Cochrane Database Syst Rev*. 2017;2:CD008716.
30. Cohen PA. Probiotic safety: no guarantees. *JAMA Intern Med*. 2018;178:1577–8. <https://doi.org/10.1001/jamainternmed.2018.5403>
31. Vallabhaneni S, Walker TA, Lockhart SR, Ng D, Chiller T, Melchreit R, et al.; Centers for Disease Control and Prevention (CDC). Notes from the field: fatal gastrointestinal mucormycosis in a premature infant associated with a contaminated dietary supplement – Connecticut, 2014. *MMWR Morb Mortal Wkly Rep*. 2015;64:155–6.
32. Egervärn M, Lindmark H, Olsson J, Roos S. Transferability of a tetracycline resistance gene from probiotic *Lactobacillus reuteri* to bacteria in the gastrointestinal tract of humans. *Antonie van Leeuwenhoek*. 2010;97:189–200. <https://doi.org/10.1007/s10482-009-9401-0>
33. Shen NT, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, et al. Timely use of probiotics in hospitalized adults prevents *Clostridium difficile* infection: a systematic review with meta-regression analysis. *Gastroenterology*. 2017;152:1889–1900.e9. <https://doi.org/10.1053/j.gastro.2017.02.003>
34. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical Practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis*. 2018;66:987–94. <https://doi.org/10.1093/cid/ciy149>
35. Su GL, Ko CW, Bercik P, Falck-Ytter Y, Sultan S, Weizman AV, et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. *Gastroenterology*. 2020;159:697–705. <https://doi.org/10.1053/j.gastro.2020.05.059>

Address for correspondence: Juha Rannikko, Department of Internal Medicine, Tampere University Hospital, Box 2000, FI-33521 Tampere, Finland; email: juha.rannikko@gmail.com